-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ImmunoGen (NASDAQ:IMGN) Now Covered by Barclays
ImmunoGen (NASDAQ:IMGN) Now Covered by Barclays
Investment analysts at Barclays assumed coverage on shares of ImmunoGen (NASDAQ:IMGN – Get Rating) in a research note issued on Friday, MarketBeat reports. The brokerage set an "overweight" rating and a $8.00 price target on the biotechnology company's stock. Barclays's price target indicates a potential upside of 46.52% from the company's current price.
Separately, StockNews.com lowered ImmunoGen from a "hold" rating to a "sell" rating in a research report on Monday, August 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, ImmunoGen has an average rating of "Hold" and an average target price of $9.80.
Get ImmunoGen alerts:ImmunoGen Stock Performance
NASDAQ:IMGN opened at $5.46 on Friday. The firm has a market cap of $1.21 billion, a PE ratio of -7.91 and a beta of 0.90. ImmunoGen has a fifty-two week low of $3.10 and a fifty-two week high of $7.77. The business has a 50 day moving average price of $5.39 and a 200-day moving average price of $4.84.
ImmunoGen (NASDAQ:IMGN – Get Rating) last announced its quarterly earnings results on Friday, July 29th. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.03). ImmunoGen had a negative return on equity of 67.02% and a negative net margin of 179.64%. The business had revenue of $14.20 million during the quarter, compared to analysts' expectations of $16.18 million. During the same period in the previous year, the business earned ($0.15) EPS. The business's revenue was down 16.0% compared to the same quarter last year. Research analysts predict that ImmunoGen will post -0.89 EPS for the current year.Institutional Investors Weigh In On ImmunoGen
Several large investors have recently bought and sold shares of IMGN. Northern Trust Corp boosted its position in ImmunoGen by 1.0% in the fourth quarter. Northern Trust Corp now owns 2,129,508 shares of the biotechnology company's stock worth $15,801,000 after purchasing an additional 21,104 shares during the last quarter. Swiss National Bank lifted its position in shares of ImmunoGen by 0.8% during the 4th quarter. Swiss National Bank now owns 445,300 shares of the biotechnology company's stock valued at $3,304,000 after buying an additional 3,500 shares in the last quarter. Bank of America Corp DE lifted its position in shares of ImmunoGen by 34.1% during the 4th quarter. Bank of America Corp DE now owns 1,083,865 shares of the biotechnology company's stock valued at $8,042,000 after buying an additional 275,868 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of ImmunoGen by 4.1% during the 4th quarter. BNP Paribas Arbitrage SA now owns 61,561 shares of the biotechnology company's stock valued at $457,000 after buying an additional 2,406 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new position in shares of ImmunoGen during the 4th quarter valued at about $77,000. 95.58% of the stock is currently owned by institutional investors.
ImmunoGen Company Profile
(Get Rating)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
See Also
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
Investment analysts at Barclays assumed coverage on shares of ImmunoGen (NASDAQ:IMGN – Get Rating) in a research note issued on Friday, MarketBeat reports. The brokerage set an "overweight" rating and a $8.00 price target on the biotechnology company's stock. Barclays's price target indicates a potential upside of 46.52% from the company's current price.
據MarketBeat報道,巴克萊的投資分析師在週五發佈的一份研究報告中假設了免疫系統(納斯達克:IMGN-GET評級)的股票。該經紀公司為這家生物技術公司的股票設定了“增持”評級和8.00美元的目標價。巴克萊的目標價顯示,該公司目前的股價有46.52%的潛在上行空間。
Separately, StockNews.com lowered ImmunoGen from a "hold" rating to a "sell" rating in a research report on Monday, August 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, ImmunoGen has an average rating of "Hold" and an average target price of $9.80.
另外,StockNews.com在8月1日星期一的一份研究報告中將免疫系統的評級從“持有”下調至“賣出”。一名投資分析師對該股的評級為賣出,兩名分析師給出了持有評級,三名分析師給出了該公司的買入評級。根據MarketBeat的數據,平均評級為持有,平均目標價為9.80美元。
ImmunoGen Stock Performance
ImmunoGen股票表現
NASDAQ:IMGN opened at $5.46 on Friday. The firm has a market cap of $1.21 billion, a PE ratio of -7.91 and a beta of 0.90. ImmunoGen has a fifty-two week low of $3.10 and a fifty-two week high of $7.77. The business has a 50 day moving average price of $5.39 and a 200-day moving average price of $4.84.
納斯達克:IMGN上週五開盤報5.46美元。該公司的市值為12.1億美元,市盈率為-7.91,貝塔係數為0.90。ImmunoGen的股價為52周低點3.10美元,52周高點為7.77美元。該業務的50日移動均線價格為5.39美元,200日移動均線價格為4.84美元。
Institutional Investors Weigh In On ImmunoGen
機構投資者對免疫基因的看法
Several large investors have recently bought and sold shares of IMGN. Northern Trust Corp boosted its position in ImmunoGen by 1.0% in the fourth quarter. Northern Trust Corp now owns 2,129,508 shares of the biotechnology company's stock worth $15,801,000 after purchasing an additional 21,104 shares during the last quarter. Swiss National Bank lifted its position in shares of ImmunoGen by 0.8% during the 4th quarter. Swiss National Bank now owns 445,300 shares of the biotechnology company's stock valued at $3,304,000 after buying an additional 3,500 shares in the last quarter. Bank of America Corp DE lifted its position in shares of ImmunoGen by 34.1% during the 4th quarter. Bank of America Corp DE now owns 1,083,865 shares of the biotechnology company's stock valued at $8,042,000 after buying an additional 275,868 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of ImmunoGen by 4.1% during the 4th quarter. BNP Paribas Arbitrage SA now owns 61,561 shares of the biotechnology company's stock valued at $457,000 after buying an additional 2,406 shares in the last quarter. Finally, HighTower Advisors LLC purchased a new position in shares of ImmunoGen during the 4th quarter valued at about $77,000. 95.58% of the stock is currently owned by institutional investors.
幾家大型投資者最近買賣了IMGN的股票。北方信託公司在第四季度將其在ImmunoGen的頭寸增加了1.0%。北方信託公司現在擁有2,129,508股生物技術公司的股票,價值15,801,000美元,在上個季度額外購買了21,104股。瑞士國家銀行在第四季度將其在ImmunoGen的股票頭寸提高了0.8%。瑞士國家銀行現在持有這家生物技術公司44.53萬股股票,價值330.4萬美元,上個季度又購買了3500股。第四季度,美國銀行(Bank Of America Corp DE)將其在ImmunoGen股票中的頭寸提高了34.1%。美國銀行(Bank Of America Corp DE)目前持有這家生物技術公司1,083,865股股票,價值8,042,000美元,上一季度又購買了275,868股。法國巴黎銀行套利公司在第四季度將其在ImmunoGen股票的頭寸提高了4.1%。法國巴黎銀行套利公司現在擁有61,561股這家生物技術公司的股票,價值45.7萬美元,在上個季度又購買了2,406股。最後,HighTower Advisors LLC在第四季度購買了免疫系統公司的新頭寸,價值約77,000美元。95.58%的股票目前由機構投資者持有。
ImmunoGen Company Profile
免疫遺傳公司簡介
(Get Rating)
(獲取評級)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
免疫基因公司是一家臨牀階段的生物技術公司,開發抗體-藥物結合(ADC)療法來治療癌症。該公司的候選產品包括針對葉酸受體α(FRA)的ADC Mirvetuximab soravtansine,它正處於治療對鉑耐藥的卵巢癌的第三階段臨牀試驗;以及Pivekimab Sunirine,一種針對CD123的ADC,正處於治療急性髓系白血病和原始漿細胞樣樹突狀細胞腫瘤的第二階段臨牀試驗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免費獲取StockNews.com關於免疫基因的研究報告(IMGN)
- MarketBeat:回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
- 汽車市場正在緩慢復甦,這些股票可能表現優異
- DocuSign是否即將發生重大逆轉?
- 石油和天然氣股票:投資可再生能源的安全途徑
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫基因日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對免疫系統及相關公司評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧